СИСТОЛИЧЕСКАЯ АРТЕРИАЛЬНАЯ ГИПЕРТОНИЯ: МЕСТО БЛОКАТОРОВ РЕЦЕПТОРОВ АНГИОТЕНЗИНА II
Аннотация
Систолическая артериальная гипертония: место блокаторов рецепторов ангиотензина II.
Об авторе
Д. В. Небиеридзе
Государственный научно-исследовательский центр профилактической медицины Минздрава РФ, Москва
Россия
Россия
Список литературы
1. Stamler J. Stamler R. Blood pressure systolic and diastolic, and cardiovascular risks. Arch. Intern. Med. 1993, 153, 598-615.
2. Kannel W., Gordon T., Schwartz M. Systolic versus diastolic blood pressure and risk of coronary heart disease. The Framingham study. Am. J. Cardiol. 1997. 127. 335-346.
3. Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure 6th Report. Arch. Intern. Med. 1997, 157, 2413-2446.
4. World Health Organization-International Society of Hypertension 1999 WHO/ISH guidelines for the management of hypertension. J. Hypertens., 1999. 17 151-183.
5. Lloyd-Jones D., Evans J et al. Differential impact of systolic and diastolic blood pressure level on JNC-YI staging. Hypertension, 1999,34,381-385.
6. Stokes J., Kannel W., Wolf P et al. Blood pressure as a risk factor for cardiovascular disease.The Framingham Study: 30 years of follow-up.Hypertension,1989,13 (suupl.1), 1-13-1-18.
7. Whelton P. In Cardiovascular Risk Management, July 1999, Pub: Gardiner-Caldwell Communikations Ltd, Macclesfield, England
8. SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program. JAMA, 1991 265. 3255-3264.
9. Staessen J. Fagard R. Thijs L. Et al. al. Randomized, double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. Lancet, 1997. 350 757-764.
10. Liu L. Wang J. Gong L. et al. for the Systolic Hypertension in China (Syst-China) collaborative group. Comparison of active treatment and placebo for older patients with isolated systolic hypertension. J. Hypertens., 1998. 16 1823-1829.
11. Swales J. In Cardiovascular Risk Management, July 1999, Pub: Gardiner-Caldwell Communikations Ltd, Macclesfield, England
12. Hansson L. Zanchetti A. Carruthers S. et al. Effects of intensive blood presure lowering and low-dose aspirin in patients with hypertension principal results of the Hypertension Optimal Treatment (HOT) randomized trial. Lancet. 1998. 351. 1755- 1762.
13. Brooks D., Ohlstein E., Ruffolo R. Pharmacology of eprosartan an angiotensin II receptor agonist exploring hypotesis from clinical data Am. Heart J. 1999, 138. S247-S251.
14. Cox S.L., Story D.F., Ziogas J. Multiple prejunctional actions of angiotensin II on noradrenergic transmission in the caudal artery of the rat// Br. J.Pharmacol. 1996, 119; 976-84.
15. Criscione L., de Gasparo M., Buhlmayer P. et. Al.Pharmacological profile of valsartan: a potent, orally active, nonpeptide antagonist of the angiotensin II AT, receptor sybtype// Br. J.Pharmacol. 1993, 110; 761-71.
16. Ohlstein E.H., Brooks D.P., Feuerstein G.Z., Ruffolo R.R. Inhibition of sympathetic outflow by the angiotensin II receptor antagonist, eprosartan, but not by losartan, valsartan or irbesartan; relationship to differences in prejunctional angiotensin II receptor blockade// Pharmacology. 1997; 55(5): 244-51.
17. Sega K.Efficacy and safety of eprosartan in severe hypertension. Blood Pressure,1999,8,114-121
18. ИвановаО.В., БалахоноваТ.В., СоболеваГ.Н. идр. Состояние эндотелий-зависимой вазодилатации плечевой артерии у больных гипертонической болезнью, оцениваемое с помощью ультразвука высокого разрешения. Кардиология 1997:7: 41 –46.
19. Celermajer D.S., Sorensen K.E., Gooch V.M. et al. Non – invasive detection of endotelial dysfunction in childeren and adults at risk of atherosclerosis. Lancet 1992; 340: 1111 – 1115.
20. Barone F., Chandra S., Nelson., A. et al. Eprosartan reduces cardiomyopathy,improves ultrasound and MRI indicies of cardiac function, improves renal function and eliminates mortality in stroke prone rats. Ninth European Meeting on Hypertension., Milan, 11-15 June 1999.
Рецензия
Для цитирования:
Небиеридзе Д.В. СИСТОЛИЧЕСКАЯ АРТЕРИАЛЬНАЯ ГИПЕРТОНИЯ: МЕСТО БЛОКАТОРОВ РЕЦЕПТОРОВ АНГИОТЕНЗИНА II. Российский кардиологический журнал. 2002;(1):35-37.
For citation:
Nebieridze D.V. SYSTOLIC ARTERIAL HYPERTENSION: THE PLACE OF ANGIOTENSIN II RECEPTOR BLOCKERS. Russian Journal of Cardiology. 2002;(1):35-37. (In Russ.)
Просмотров:
297
Послать статью по эл. почте 